Compare Natera Inc. Common Stock (NTRA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Revvity Inc — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Revvity Inc trades at $155 (market cap $16.97B). The key difference: Natera Inc. Common Stock is far larger — about 3.4× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Revvity Inc for 13 Days on average.
| NTRA | RVTY | |
|---|---|---|
Market Cap | $57.03B | $16.97B |
Volume | 1,131,157 | 1,602,713 |
Sector | Health | Health |
52-Week High | $425.64 | $157.36 |
52-Week Low | $179.42 | $82.26 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $56.18B | $19.29B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RVTY trades at $155.08, down 0.34% today but near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving average support. Recent earnings beats and a Zacks upgrade to Buy reflect positive momentum. The company launched a new Type 1 diabetes screening kit in Europe and announced the acquisition of Human Cell Design, expanding its metabolic disease research tools.
Outlook remains positive with revenue stability and margin pressures manageable. Investment opportunity lies in diagnostic growth and AI-driven demand, though premium valuation and China market risks warrant caution. The absence of sell ratings and strong institutional accumulation support a constructive view, but rich multiples require sustained earnings delivery for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
